515 / 1631
Outline of talk
• Early stage –
Is Radiotherapy still standard ?
• Advanced stage
– Low volume asymptomatic –
Is watch and wait still standard ?
– High volume or symptomatic :
standards of care in Immuno-chemotherapy ?
• Relapsed / refractory disease –
How do we predict patients who may
require different treatment approaches ?
• Radioimmunotherapy –
Is there still an opportunity ?
• Targeted Therapies –
Is there life with and after PI3K inhibitors ?